Neville Sanjana’s lab develops technologies to understand how human genetic variants cause diseases of the nervous system and cancer. The lab employs a multi-disciplinary approach, combining genome engineering, pooled genetic screens, bioinformatics, electrophysiology, and imaging, to dissect the inner workings of the human genome and its dysfunction in autism and tumor evolution. The Sanjana lab is comprised of molecular engineers, biologists, neuroscientists, computer scientists and bioscience entrepreneurs who are passionate about creating new technologies for genomics and advancing human health. To find out more about current projects and open positions in the Sanjana lab, please visit the lab webpage.
The lab is also affiliated with the Department of Biology at New York University.
Neville Sanjana, PhD, is a Core Faculty Member at the New York Genome Center (NYGC). He holds a joint appointment as Assistant Professor in the Department of Biology at NYU and is an Assistant Professor of Neuroscience and Physiology at the NYU School of Medicine.
As a bioengineer, Dr. Sanjana is focused on creating new tools to understand the impact of genetic changes on the nervous system and cancer evolution. His research interests include bioengineering, genomics, neuroscience, cancer biology and systems biology.
The Sanjana Lab develops new technologies and tools to understand how human genetic variants cause diseases of the nervous system and cancer. Dr. Sanjana and his research team use a multi-disciplinary approach, combining genome engineering, pooled genetic screens, bioinformatics, electrophysiology, and imaging, to dissect the inner workings of the human genome and its dysfunction in tumor evolution and autism.
Utilizing new technologies for large-scale DNA synthesis, gene editing and next-generation sequencing, the Sanjana Lab has developed pooled screening approaches for functional genomics, creating CRISPR libraries to target the noncoding genome. Dr. Sanjana has identified novel genetic drivers of melanoma drug resistance, drivers of metastasis in vivo, and mechanisms used by tumors to evade immunotherapy. One of the major goals of the Sanjana Lab is to continue expanding the genome engineering toolbox to further scientific understanding of the noncoding genome and its vital role in human health and disease.
A recipient of the Kimmel Scholar Award and the NIH Pathway to Independence Award, Dr. Sanjana is also a Next Generation Leader for the Paul Allen Institute for Brain Science. Prior to joining the NYGC and NYU, he was a Simons Postdoctoral Fellow at the Broad Institute of Harvard and MIT. Dr. Sanjana holds a PhD in Brain and Cognitive Sciences from MIT, a BS in Symbolic Systems and a BA in English from Stanford University.
Target Discovery for Precision Medicine Using High-Throughput Genome Engineering.
Guo X, Chitale P, Sanjana NE.
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1016). Chapter First Online: 2017
High-Throughput Approaches to Pinpoint Function within the Noncoding Genome.
Montalbano A, Canver, MC and Sanjana NE.
Molecular Cell. 2017 Oct. 5.
GUIDES: sgRNA design for loss-of-function screens.
Nature Methods. 2017 August 31.
Identification of essential genes for cancer immunotherapy.
Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia, L, Steinberg SM, Yamamoto TN, Merchant, AS, Mehta, GU, Chichura A, Shalem O, Tran E, Eil, R, Sukumar M, Perez Guijarro E, Day C-P, Robbins P, Feldman S, Merlino G, Zhang F, Restifo, NP.
Nature. 2017 August 7.
Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening.
Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, Sanjana NE, Zhang F.
Nature Protocols. 2017 Mar 23.
- Target Discovery for Precision Medicine Using High-Throughput Genome Engineering.